Characterization of drugs as antioxidant prophylactics

Free Radical Biology and Medicine

Volumn 20, Issue 5, 1996, Pages 675-705

  Aruoma, Okezie I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antioxidants; Drug design; Free radicals; Human diseases; Oxidative stress

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYL RADICAL; HYPOCHLOROUS ACID; NITRIC OXIDE;

CANCER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DESIGN; INFECTION; LIPID PEROXIDATION; MICROSOME; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

EID: 0030003733     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/0891-5849(95)02110-8     Document Type: Review

References (473)

1. Gomberg, M. An incidence of trivalent carbon trimethylphenyl. J. Am. Chem. Soc. 22:757-771; 1900.
2. Hey, D. H.; Waters, W. A. Some organic reactions involving the occurrence of free radicals in solution. Chem. Rev. 21:169-208; 1937.
3. Cadogan, J. I. G. Principles of free radical chemistry. London: The Chemical Society; 1973.
4. 2 in solution. Trans. Faraday Soc. 31:668-681; 1935.
5. Wallings, C. Free radicals in solution. London: Wiley; 1957.
6. Pryor, W. A. Free radicals. New York: McGraw Hill; 1966.
7. Gerschman, R.; Gilbert, D. L.; Nye, S. W.; Dwyer, P.; Fenn, W. O. Oxygen poisoning and x-irradiation: A mechanism in common. Science 119:623-626; 1954.
8. McCord, J. M.; Fridovich, I. Superoxide dismutase: An enzymatic function for erythrocuprein (hemocuprein). J. Biol. Chem. 224:6049-6055; 1969.
9. Fridovich, I. Superoxide radical: An endogenous toxicant. Annu Rev. Pharmacol. Toxicol. 23:239-257; 1983.
10. Halliwell, B.; Gutteridge, J. M. C. Free radicals in biology and medicine. Oxford: Clarendon Press; 1989.
11. Pryor, W. A. Free radical biology: Xenobiotics, cancer and aging. Ann. NY Acad. Sci. 393:1-22; 1982.
12. Slater, T. F. Free radicals in medicine. Free Radic. Res. Commun. 7:119-390; 1989.
13. Goldstein, S.; Meyerstein, D.; Czapski, G. The Fenton reagents. Free Radic. Biol. Med. 15:435-445; 1993.
14. Aruoma, O. I. Free radicals in tropical diseases. London: Harwood Academic Publishers; 1993.
15. Babior, B. M. Oxidants from phagocytes: Agents of defense and destruction. Blood 64:959-966; 1984.
16. Sies, H., ed. Oxidative stress. London: Academic Press; 1985.
17. Bensasson, R. V.; Land, E. J.; Truscott, T. G. Excited states and free radicals in biology and medicine, contribution from flash photolysis and pulse radiolysis. Oxford: Oxford University Press; 1993.
18. Armstrong, D.; Sohal, R. S.; Cutler, R. G.; Slater, T. F. Free radicals in molecular biology, aging and disease. New York: Raven Press; 1984.
19. Del Maestro, R. F. An approach to free radicals in medicine and biology. Acta Physiol. Scand Suppl. 492:153-168; 1980.
20. Slater, T. F. Activation of carbon tetrachloride: Chemical principles and biological significance. In: McBrien, D. C. H.; Slater, T. F., eds. Free radicals, lipid peroxidation and cancer. New York: Academic Press; 1982:243-273.
21. Recknagel, R. O.; Glande, E. A., Jr.; Dolak, J. A.; Waller, R. L. Mechansims of carbon tetrachloride toxicity. Pharmacol. Ther. 43:139-154; 1989.
22. Haber, F.; Weiss, J. J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc. R. Soc. Lond. [A] 147:332-352; 1934.
23. Fenton, H. J. H. Oxidation of tartaric acid in the presence of iron. J. Chem. Soc. Trans. 65:899-910; 1894.
24. Walling, C. Fenton's reagent revisited. Acc. Chem. Res. 8:125-131; 1975.
25. Koppenol, W. H. The centennial of the Fenton reaction. Free Radic. Biol. Med. 15:645-651; 1993.
26. Diplock, A. T. Antioxidant and disease prevention. Mol. Asp. Med. 15:293-376; 1994.
27. Maxwell, S. R. J. Prospects for the use of antioxidant therapies. Drugs 49:345-361; 1995.
28. Clemens M. R. Antioxidant therapy in haematological disorders. Adv. Exp. Biol. Med. 264:423-433; 1990.
29. Hearse, D. J. Prospects for antioxidant therapy in cardiovascular medicine. Am. J. Med. 91:1188-1218; 1991.
30. Halliwell, B. Drug antioxidant effect. A basis for drug selection. Drugs 42:569-605; 1991.
31. Rice-Evans, C. A.; Diplock, A. T. Current status of antioxidant therapy. Free Radic. Biol. Med. 15:77-96; 1993.
32. Cross, C. E. HIV-1 infection. The role of oxidants. In: Aruoma, O. I., ed. Free radicals in tropical diseases. London: Harwood Academic Publishers; 1993:167-185.
33. Ames, B. N.; Shigenaga, M. K.; Hagen, T. M. Oxidants, antioxidants, and the degenerative disease of aging. Proc. Natl. Acad. Sci. USA 90:7915-7922; 1993.
34. Ganguly, P. K. Antioxidant therapy in congestive heart failure: Is there any advantage? J. Inter. Med. 229:205-208; 1991.
35. Greenspan, H.; Aruoma, O. I. Oxidative stress and apoptosis in HIV infection: A role for plant-derived metabolites with synergistic antioxidant activity. Immunol. Today 15:209-213; 1994.
36. Riemersma, R. A.; Wood, D. A.; Macintyre, C. C.; Elton, R. A.; Gey, K. F.; Oliver, M. F. Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotenes. Lancet 337:1-5; 1991.
37. Aruoma, O. I. Nutrition and health aspects of free radicals and antioxidants. Fd Chem. Toxicol. 32:671-683; 1994.
38. Packer, L. Health effects of nutritional antioxidants. Free Radic. Biol. Med. 15:685-686; 1993.
39. Haumann, B. F. Antioxidants: Health implications. INFORM 5:242-252; 1994.
40. Ho, N.; Hirose, M. Antioxidants: Carcinogenic and chemopreventative properties. Adv. Cancer Res. 53:247-302; 1989.
41. Bonorden, W. R.; Pariza, M. W. Antioxidant nutrients and protection from free radicals. In: Kotsonis, F. N.; Mackey, M.; Hjelle, J., eds. Nutritional toxicology. New York: Raven Press; 1994:19-48.
42. Cerutti, P. A.; Fridovich, I.; McCord, J. M., eds. Oxy-radicals in molecular biology and pathology. New York: Alan R. Liss; 1988.
43. Roche, A. F., ed. Oxidative processes and antioxidants. Their relation to nutrition and health outcomes. Report of the Thirteenth Ross Conference on Medical Research, Ross Products. OH: Abbott Laboratories; 1994.
44. Frei, B., ed. Natural antioxidants in human health and disease. New York: Academic Press; 1994.
45. Scrip Reports. Reactive oxygen and oxidative stress a new route for tackling disease? London: PJB Publications Ltd.; 1994.
46. Southorn, P. A.; Powis, G. Free radicals in medicine II, involvement in human disease. Mayo Clin. Proc. 63:390-408; 1988.
47. McCord, J. M. Human disease, free radicals and the oxidant/ antioxidant balance. Clin. Biochem. 26:351-357; 1993.
48. Chan, H.-W. S., ed. Auto-oxidation of unsaturated lipid. London: Academic Press; 1987.
49. Hudson, B. J. F., ed. Food antioxidants. Amsterdam: Elsevier; 1990.
50. Löliger, J. The use of antioxidants in foods. In: Aruoma, O. I.; Halliwell, B., eds. Free radicals and food additives. London: Taylor & Francis; 1991:121-150.
51. Shahidi, F.; Wanasundara, J. P. K. P. D. Phenolic antioxidants. Crit. Rev. Food Sci. Nutr. 32:67-103; 1992.
52. Ladikos, D.; Lougovois, V. Lipid oxidation in muscle foods: A review. Food Chem. 35:295-314; 1990.
53. Williams, G. M., ed. Antioxidants: Chemical, physiological, nutritional and toxicological aspects. Princeton: Princeton Scientific; 1993.
54. Mehta, A. C.; Seshadri, T. R. Flavonoids as antioxidants. J. Sci. Ind. Res. India 18B:24-28. 1959.
55. Javanovic, S. V.; Steenken, S.; Tosci, U.; Marjanovic, B.; Simic, M. G. Flavonoids as antioxidants. J. Am. Chem. Soc. 116:4846-4851; 1994.
56. Aruoma, O. I.; Halliwell, B. Free radicals and food additives. London: Taylor & Francis; 1991.
57. Aruoma, O. I. Free radicals: Their role in nutrition. In: Aruoma, O. I., ed. Free radicals in tropical diseases. London: Harwood Academic Publishers; 1993:187-217.
58. St. Angelo, A. J. Lipid oxidation in food. ACS symposium series 500. Washington, DC: American Chemical Society; 1992.
59. Shahidi, F.; Rubin, L. J.; Wood, D. F. Control of lipid oxidation in cooked ground pork with antioxidants and dinitrosylferro-hemochrome. J. Food Sci. 52:564-567; 1987.
60. Robinson, D. S.; Eskin, N. A. M. Oxidative enzymes in foods. London: Elsevier Applied Science; 1991.
61. Ramanathan, L.; Das, N. P. Studies on the control of lipid oxidation in ground fish by some polyphenolic natural products. J. Agric. Food Chem. 40:17-21; 1992.
62. Porter, W. L. Paradoxical behaviour of antioxidants in food and biological systems. In: Williams, G. M., ed. Antioxidants: Chemical, physiological, nutritional and toxicological aspects. Princeton: Princeton Scientific; 1993:93-122.
63. Taguchi, K.; Iwami, K.; Ibuki, F.; Kawabata, M. Oxidative stability of sardine oil embedded in spray-dried egg white powder and its use for n-3 unsaturated fatty acid fortification of cookies. Biosci. Biotechnol. Biochem. 56:560-563; 1992.
64. Kim, S. Y.; Kim, J. H.; Kim, S. K.; Oh, M. J.; Jung, M. Y. Antioxidant activities of selected oriental herb extracts. J. Am. Oil. Chem. Soc. 71:633-640; 1994.
65. van Zoeren-Grobben, D.; Moison, R. M. W.; Ester, W. M.; Berger, H. M. Lipid peroxidation in human milk and infant formula: Effect of storage, tube feeding and exposure to phototherapy. Acta Paediatr. 82:645-649; 1993.
66. Halliwell, B.; Cross, C. E.; Gutteridge, J. M. C. Free radicals, antioxidants and human disease. Where are we now? J. Lab. Clin. Med. 119:598-620; 1992.
67. Dix, T. A.; Aikens, J. Mechanism and biological relevance of lipid peroxidation. Chem. Res. Toxicol. 6:2-18; 1993.
68. Foti, M.; Ingold, K. U.; Lusztyk, J. The surprising high reactivity of phenoxyl radicals. J. Am. Chem. Soc. 116:9440-9447; 1994.
69. Dargel, R. Lipid peroxidation: A common pathogenic mechanism. Exp. Toxicol. Pathol. 44:169-181; 1992.
70. Liebler, D. C. The role of metabolism in the antioxidant function of vitamin E. Crit. Rev. Toxicol. 23:147-169; 1993.
71. Chan, K. M.; Decker, E. A. Endogenous skeletal muscle antioxidant. Crit. Rev. Food Sci. Nutr. 34:403-426; 1994.
72. Frei, B.; Kim, M. C.; Ames, B. N. Ubiquinol-10 is an effective lipid soluble antioxidant at physiological concentrations. Proc. Natl. Acad. Sci. USA 87:4879-4833; 1990.
73. Halliwell, B. Vitamin C: The key to health or a slow acting carcinogen? Redox Rep. 1:5-9; 1994.
74. Rose, R. C.; Bode, A. M. Biology of free radical scavengers: An evaluation of ascorbate. FASEB J. 7:1135-1142; 1993.
75. Pryor, W. A. Measurement of oxidative stress status in humans. Cancer Epidemiol. Biomark Prev. 2:289-292; 1993.
76. Sies, H. Strategies of antioxidant defense. Eur. J. Biochem. 215:213-219; 1993.
77. Halliwell, B. Free radicals and antioxidants. Nutr. Rev. 52:253-265; 1994.
78. Aruoma, O. I. Free radicals and antioxidant strategies in sports. J. Nutr. Biochem. 5:370-381; 1994.
79. Rickwood, S. Global pharmaceuticals. London: Financial Times Management Reports; 1993.
80. Spilker, B. Multinational pharmaceutical companies: Principles and practices, 2nd ed. New York: Raven Press; 1993.
81. Halliwell, B. How to characterize a biological antioxidant. Free Radic. Res. Commun. 9:1-32; 1990.
82. Aruoma, O. I. Deoxyribose assay for detecting hydroxyl radicals. Methods Enzymol. 233:57-66; 1994.
83. Aruoma, O. I.; Murcia, A.; Butler, J.; Halliwell, B. Evaluation of the antioxidant actions of gallic acid and its derivatives. J. Agric. Food Chem. 41:1880-1885; 1993.
84. Halliwell, B.; Gutteridge, J. M. C.; Aruoma, O. I. The deoxyribose method: A simple test-tube assay for determination of rate constants for reaction of hydroxyl radical. Anal. Biochem. 165:215-219; 1987.
85. van den Berg, J.; Winterbourn, C. Measurement of reaction products from hypochlorous acid and unsaturated lipids. Methods Enzymol. 233:639-649; 1994.
86. Aruoma, O. I.; Halliwell, B. Action of hypochlorous acid on the antioxidant protective enzyme superoxide dismutase, catalase and glutathione peroxidase. Biochem. J. 248:973-976; 1987.
87. Pryor, W. A.; Cornicelli, J. A.; Devall, L. J.; Tait, B.; Trivedi, B. K.; Witiak, D. T.; Wu, M. A rapid screening test to determine the antioxidant potencies of natural and synthetic antioxidants. J. Org. Chem. 58:3521-3532; 1993.
88. Miller, N. J.; Rice-Evans, C. A.; Davies, M. J.; Gopinathan, V.; Milner, A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin. Sci. 84:407-412; 1993.
89. Brand-Williams, W.; Cuvelier, M. E.; Berset, C. Use of a free radical method to evaluate antioxidant activity. Lebensm-Wiss, U. Technol. 28:25-30; 1995.
90. Halliwell, B.; Aeschbach, R.; Löliger, R.; Aruoma, O. I. The characterization of antioxidants. Fd. Chem. Toxicol. 33:601-617; 1995.
91. Mahmood, N.; Cosime, P.; Aquine, R.; De Tommasi, N.; Pincente, S.; Coleman, S.; Burke, A.; Hay, A. J. Inhibition of HIV infection by flavonoids. Antivir. Res. 22:189-199; 1993.
92. 14C tracer and product studies. Biochim. Biophys. Acta 1237:77-85; 1995.
93. Klöpffer, W.; Kohl, E. G. Bimolecular OH rate constants or organic compounds in solution. II. Measurements in 1,2,2,trichlorotrifluoroethane using hydrogen peroxide as an OH source. Ecotoxicol. Environ. Safety 26:346-356; 1993.
94. Zhao, M. J.; Jung, L.; Tanielian, C.; Mechin, R. Kinetics of the competitive degradation of deoxyribose and other biomolecules by hydroxyl radicals produced by the Fenton reaction. Free Radic. Res. 20:345-363; 1994.
95. Bagachi, D.; Bagachi, M.; Hassoun, E. A.; Stohs, S. J. Detection of paraquat-induced in vivo lipid peroxidation by gas chromatography/mass spectrometry and high pressure lipid chromatography. J. Anal. Toxicol. 17:411-414; 1993.
96. 2α rises in response to hydroxyl radical generated in vivo. Free Radic. Biol. Med. 18: 571-576; 1995.
97. Ching, T. L.; de Jong, J.; Bast, A. A method for screening hypochlorous acid scavengers by inhibition of the oxidation of 5-thio-2-nitro-benzoic acid: Application of antiasthmatic drugs. Anal. Biochem. 218:377-381; 1994.
98. Beckman, J. S.; Ye, Y. Z.; Anderson, P. G.; Chen, J.; Accavitti, M. A.; Tarpey, M.; White, C. R. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biochem. Hoppe-Seyler 375:81-88; 1994.
99. Kaur, H.; Halliwell, B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fuid from rheumatoid patients. FEBS Lett. 350:9-12; 1994.
100. Maskos, Z.; Rush, J. D.; Koppenol, W. The hydroxylation of the salicylate anion by a Fenton reaction and radiolysis: A consideration of respective mechanisms. Free Radic Biol. Med. 8:153-162; 1990.
101. Sun, J.-Z.; Kaur, H.; Halliwell, B.; Li, X. Y.; Bolli, R. Use of aromatic hydroxylation of phenylalanine to measure production of hydroxyl radicals after myocardial ischemia in vivo. Direct evidence for a pathogenic role of hydroxyl radical in myocardial stunning. Circ. Res. 73:534-549; 1993.
102. Grootveld, M.; Halliwell, B. Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo: Identification of hydroxylated derivatives of salicylate in human fluids. Biochem. J. 237:499-504; 1986.
103. Maskos, Z.; Rush, J. D.; Koppenol, W. H. The hydroxylation of tryptophan. Arch. Biochem. Biophys. 296:514-520; 1992.
104. Karam, L. R.; Bergtold, D. S.; Simic, M. G. Biomarkers of OH radical damage in vivo. Free Radic. Res. Commun. 12-13:11-16; 1991.
105. Zweier, J. L. Measurement of superoxide-derived free radicals in the reperfused heart. J. Biol. Chem. 263:1353-1357; 1988.
106. Pietri, S.; Culcasi, M.; Cozzonem, P. J. Real time continuous-flow spin trapping of hydroxyl free radical in the ischemic and postischemic myocardium. Eur. J. Biochem. 186:163-173; 1989.
107. Zweier, J. L.; Kuppusamy, P.; William, R.; Rayburn, B. K.; Smith, D.; Weisfeldt, M. L.; Flaherty, J. T. Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J. Biol. Chem. 264:18890-18895; 1989.
108. Shufer, S. L.; Davies, M. J.; Garlick, P. B.; Hearse, D. J.; Slater, T. F. Studies on the effects of antioxidants and inhibitors of radical generation on free radical production in the reperfused rat heart using electron spin resonance spectroscopy. Free Radic. Res. Commun. 9:223-232; 1990.
109. Pincemail, J.; Defraigne, J. O.; Franssen, C.; Bonnet, P.; Deby-Dupont, G.; Pirenne, J.; Deby, C.; Lamy, M.; Limet, M.; Meurisse, M. Evidence for free radical formation during human kidney transplantation. Free Radic. Biol. Med. 15:343-348; 1993.
110. Reznick, A. Z.; Cross, C. E.; Hu, M.-L.; Suzuki, Y. J.; Khwoja, S.; Safadi, A.; Motchnik, P. A.; Packer, L.; Halliwell, B. Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochem. J. 286:607-611; 1992.
111. Levine, R. L.; Williams, J. A.; Stadtman, E. R.; Schacter, E. Carbonyl assay for determination of oxidatively modified proteins. Methods Enzymol. 233:346-356; 1994.
112. Stadtman, E. R. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal catalyzed reactions. Annu. Rev. Biochem. 62:797-821; 1993.
113. Finch, J. W.; Crouch, R. K.; Knapp, D. R.; Schey, K. L. Mass spectrometric identification of modification to human serum albumin treated with hydrogen peroxide. Arch. Biochem. Biophys. 305:595-599; 1993.
114. Reznick, A. Z.; Packer, L. Oxidative damage to proteins: Spectrophotometric method for carbonyl assay. Methods Enzymol. 233:357-362; 1994.
115. Davies, K. J. A.; Delsignore, M. E.; Lin, S. W. Protein damage and degradation by oxygen radicals. Modification of amino acids. J. Biol. Chem. 262:9902-9907; 1987.
116. Giulivi, C.; Davies, K. J. A. Dityrosine and tyrosine oxidation products are endogenous markers for the selective proteolysis of oxidatively modified red blood cell hemoglobin (by the 19s) proteosome. J. Biol. Chem. 268:8752-8759; 1993.
117. Uchida, K.; Stadtman, E. R. Quantitation of 4-hydroxynonenal protein adducts. Methods Enzymol. 233:371-379; 1994.
118. Keller, R. J.; Holmes, N. C.; Hinson, J. A.; Pumford, N. R. Immunochemical detection of oxidized proteins. Chem. Res. Toxicol. 6:430-433; 1993.
119. Griffiths, H. R.; Lunec, J.; Blake, D. R. Oxygen radical induced fluorescence in proteins: Identification of the fluorescence tyrptophan metabolite, N-formyl kynurenine as a biological index of radical damage. Amino Acids 3:183-184; 1992.
120. Shang, F.; Taylor, A. Oxidative stress and recovery from oxidative stress are associated with altered ubiquitin conjugating and proteolytic activities in bovine lens epithelial cells. Biochem. J. 307:297-303; 1995.
121. Holley, A. E.; Slater, T. F. Measurement of lipid hydroperoxide in normal human blood plasma using HPLC-chemilumines cence linked to diode array detector for measuring conjugated dienes. Free Radic. Res. Commun. 15:51-63; 1991.
122. Halliwell, B.; Chirico, S. Lipid peroxidation, its mechanism, measurement and significance. Am. J. Clin. Nutr. 57:715S-725S; 1993.
123. Dennis, K. J.; Shibamoto, T. Gas chromatographic determination of malonaldehyde formed by lipid peroxidation. Free Radic. Biol. Med. 7:187-192; 1989.
124. Thomas, D. W.; Van Kuijk, F. J. G. M.; Dratz, E. A.; Stephens, R. J. Quantitative determination of hydroxy fatty acids as an indicator of in vivo lipid peroxidation; Gas chromatography-mass spectrometry methods. Anal. Biochem. 198:104-111; 1991.
125. Morrow, J. D.; Roberts, L. J., II. Quantification of noncycloxygenase derived prostanoids as a marker of oxidative stress. Free Radic. Biol Med. 10:195-200; 1991.
126. 2-like compounds are produced in vivo in humans by a noncycloxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87:9383-9387; 1990.
127. Gutteridge, J. M. C.; Quinlan, G. J. Malondialdehyde formation from lipid peroxides in the thiobarbituric acid test: The role of lipid radicals, iron salts and metal chelators. J. Appl. Biochem. 5:293-299; 1983.
128. Aruoma, O. I.; Laughton, M. J.; Halliwell, B. Carnosine, homocarnosine and anserine: Could they act as antioxidants in vivo? Biochem. J. 264:863-869; 1989.
129. Thompson, S.; Smith, M. T. Measurement of the diene conjugated form of linoleic acid in plasma by high performance liquid chromatography; A questionable noninvasive assay of free radical activity. Chem. Biol. Interact. 55:357-366; 1985.
130. Cecchini, R.; Aruoma, O. I.; Halliwell, B. The action of hydrogen peroxide on the formation of thiobarbituric acid reactive material from microsomes, liposomes or from DNA damaged by bleomycin or phenanthroline: Artefacts in the thiobarbituric acid test. Free Radic. Res. Commun. 10:245-258; 1990.
131. Esterbauer, H.; Schaur, R. J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med. 11:81-128; 1991.
132. Esterbauer, H.; Striegl, G.; Puhl, H.; Rotheneder, M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6:67-75; 1989.
133. Hall, E. D.; Braughler, J. M. Central nervous system trauma and stroke. II: Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic. Biol. Med. 6:303-313; 1989.
134. Pompella, A.; Comporti, M. Imaging of oxidative stress at subcellular level by confocal laser scanning microscopy after fluorescent derivatization of cellular carbonyls. Am. J. Pathol. 142:1353-1357; 1993.
135. Nanji, A. A.; Khwaja, S.; Tahan, S. R.; Sadrzadeh, S. M. H. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J. Biol. Chem. 269:1280-1285; 1994.
136. Chaudhary, A. K.; Nokubo, M.; Reddy, G. R.; Yeola, S. N.; Morrow, J. D.; Blair, I. A.; Marnett, L. J. Detection of endogenous malondialdehyde deoxyguanosine adducts in human liver. Science 265:1580-1582; 1994.
137. van den Berg, J. J. M. Effects of oxidants and antioxidants evaluated using parinaric acid as a sensitive probe for oxidative stress. Redox Rep. 1:11-21; 1994.
138. Zhang, J.-R.; Cazers, A. R.; Lutzke, B. S.; Hall, E. D. HPLC-chemiluminescence and thermospray LC/MS study of hydroperoxides generated from phosphatidyl choline. Free Radic. Biol. Med. 18:1-10; 1995.
139. Holley, A. E.; Walker, M. K.; Cheeseman, K. H.; Slater, T. F. Measurement of n-alkenals and hydroxyalkenals in biological samples. Free Radic. Biol. Med. 15:281-289; 1993.
140. Draper, H. H.; Squires, E. J.; Mahmoodi, H.; Wu, J.; Agarwal, S.; Hadley, M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic. Biol. Med. 15:353-363; 1993.
141. Grootveld, M.; Halliwell, B. Measurement of allantoin and uric acid in human body fluids. A potential index of free radical reactions in vivo. Biochem. J. 243:803-808; 1987.
142. Kaur, H.; Halliwell, B. Action of biologically relevant oxidizing species upon uric acid. Identification of uric acid oxidation products. Chem. Biol. Interact. 73:235-247; 1990.
143. Ghiselli, A.; Serafini, M.; Maiani, G.; Azzini, E.; Ferro-Luzzi, A. A fluorescence-based method for measuring total plasma antioxidant capability. Free Radic. Biol. Med. 18:29-36; 1995.
144. 1-antiproteinase by hydroxyl radicals: The effect of uric acid. FEBS Lett. 244:76-80; 1989.
145. Motchnick, P. A.; Frei, B.; Ames, B. N. Measurement of antioxidants in human blood plasma. Methods Enzymol. 234:269-278; 1994.
146. Weyner, D. D. M.; Burton, G. W.; Ingold, K. U.; Locke, S. Quantitative measurement of the total peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. FEBS Lett. 187:33-37; 1985.
147. Cao, G.; Alessio, H. M.; Cutler, R. G. Oxygen radical absorbance capacity assay for antioxidants. Free Radic. Biol. Med. 14:303-311; 1993.
148. Rice-Evans, C.; Miller, N. J. Total antioxidant stutus in plasma and body fluids. Methods Enzymol. 234:279-293; 1994.
149. Vanderslice, J. T.; Higgs, D. J. Quantitative determination of ascorbic, dehydroascorbic, isoascorbic and dehydroisoascorbic acid by HPLC in foods and other matrices. J. Nutr. Biochem. 4:184-190; 1993.
150. Ward, R. J.; Jutla, J.; Peters, T. J. Antioxidant status in alcoholic liver disease. Adv. Biosci. 76:343-351; 1989.
151. Schüep, W.; Rettenmaier, R. Analysis of vitamin E homologs in plasma and tissue: High performance liquid chromatography. Methods Enzymol. 234:294-301; 1994.
152. Asensim, M.; Sastre, J.; Pallardo, F. V.; Estrela, J. M.; Vina, J. Determination of oxidized glutathione in blood: High performance liquid chromatography. Methods Enzymol. 234:367-370; 1994.
153. Tierze, F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Application to mammalian blood and other tissues. Anal. Biochem. 27:502-522; 1969.
154. Ellman, G. L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:70-77; 1959.
155. Griffith, O. W. Determination of glutathione and glutathione disulflde using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106:207-212; 1980.
156. Beauchamp, C.; Fridovich, I. Superoxide dismutase. Improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 44: 276-287; 1971.
157. Rice-Evans, C.; Diplock, A. T.; Symons, M. C. R., eds. Techniques in free radical research. London: Elsevier Applied Science; 1991.
158. Greenwald, R. A. Handbook of methods for oxygen radical research. Boca Raton, FL; CRC Press; 1985.
159. Chance, B.; Maehly, A. C. Assay of catalases and peroxidases. Methods Enzymol. 2:764-775; 1955.
160. Tappel, A. L. Glutathione peroxidase and hydroperoxides. Methods Enzymol. 52:506-513; 1978.
161. Segal, A. W.; Peters, T. J. Analytical subcellular fractionation of human granulocytes with special reference to enzymes involved in microbial mechanisms. Clin. Sci. Mol. Med. 52:429-442; 1977.
162. Perkins, M. J. Radical chemistry. London: Ellis Horwood; 1994.
163. Marnett, L. J.; Burcham, P. C. Endogenous DNA adducts: Potential and paradox. Chem. Res. Toxicol. 6:771-785; 1993.
164. Hegler, J.; Bittner, D.; Boiteux, S.; Epe, B. Quantitation of oxidative DNA modification in mitochondria. Carcinogenesis 14:2309-2312; 1993.
165. Loft, S.; Vistisen, K.; Ewertz, M.; Tjonneland, A.; Overvad, K.; Poulsen, H. E. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: Influence of smoking, gender and body mass index. Carcinogenesis 13:2441-2447; 1992.
166. Frenkel, K.; Zhong, Z.; Wei, H.; Karkozka, J.; Patel, U.; Rashia, K.; Georgescu, M.; Solomon, J. Quantitative high performance chromatography analysis of DNA oxidized in vitro and in vivo. Anal. Biochem. 196:126-136; 1991.
167. Epe, B.; Pfaum, M.; Häring, M.; Hegler, J.; Rüdiger, H. Use of repair endonucleases to characterize DNA damage induced by reactive oxygen species in cellular and cell-free systems. Toxicol. Lett. 67:57-72; 1993.
168. Floyd, R. A.; Watson, J. J.; Wong, P. K.; Altmiller, D. H.; Rickard, R. C. Hydroxyl free radical adduct of deoxyguanosine: Sensitive detection and mechanism of formation. Free Radic. Res. Commun. 1:163-172; 1986.
169. Reid, T. M.; Loeb, L. A. Effect of DNA repair enzymes on mutagenesis by oxygen free radicals. Mutat. Res. 289:181-186; 1993.
170. Halliwell, B.; Aruoma, O. I., eds. DNA and free radicals. London: Ellis Horwood; 1993.
171. Aruoma, O. I.; Halliwell, B.; Dizdaroglu, M. Iron ion dependent modification of bases in DNA by the superoxide radical generating system hypoxanthine/ xanthine oxidase. J. Biol. Chem. 264:20509-20512; 1989.
172. Halliwell, B.; Aruoma, O. I. DNA damage by oxygen derived species. Its mechanism and measurement in mammalian systems. FEBS Lett. 281: 9-19; 1991.
173. Dizdaroglu, M. Chemical determination of free radical induced damage to DNA. Free Radic. Biol. Med. 10:225-242; 1991.
174. Kasai, H.; Nishimura, S.; Kurokawa, Y.; Hayashi, Y. Oral administration of the renal carcingen, potassium bromate, specifically produces 8-hydroxydeoxyguanosine in rat target organ DNA. Carcinogenesis 8: 1959-1961; 1987.
175. Shigenaga, M. K.; Gimeno, C. J.; Ames, B. N. Urinary 8-hydroxy 2′deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc. Natl. Acad. Sci. USA 86:9697-9701; 1989.
176. Collins, A. R.; Duthie, S. J.; Dobson, V. L. Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 14:1733-1735; 1993.
177. Spencer, J. P. E.; Jenner, A.; Aruoma, O. I.; Evans, P. J.; Kaur, H.; Dexter, D. T.; Jenner, P.; Lees, A. J.; Marsden, D. C.; Halliwell, B. Intense oxidative DNA damage promoted by L-DOPA and its metabolites. Implications for neurodegenerative disease. FEBS Lett. 353:246-250; 1994.
178. Suzuki, J.; Inoue, Y.; Suzuki, S. Changes in the urinary excretion level of 8 hydroguanine by exposure to reactive oxygen generating substances. Free Radic. Biol. Med. 18:431-436; 1995.
179. Brown, R. K.; McBurney, A.; Lunec, J.; Kelly, F. J. Oxidative damage to DNA in patients with cystic fibrosis. Free Radic. Biol. Med. 18:801-806; 1995.
180. Olinski, R.; Zastawny, T. H.; Foksinski, M.; Barecki, A.; Dizdaroglu, M. DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radic. Biol. Med. 18:807-813; 1995.
181. Leray, G.; Bodell, W. J. Detection of dopamine-DNA adducts potential role in Parkinson's disease. Carcinogenesis 14:1241-1245; 1993.
182. Fuciarelli, A. F.; Wegher, B. J.; Gajewski, E.; Dizdaroglu, M.; Blakely, W. F. Quantitative measurement of radiation induced base products in DNA using gas chromatography mass spectrometry. Radiat. Res. 119:219-231; 1989.
183. Cadet, J.; Ravanat, J. L.; Buchko, G. W.; Yeo, H. C.; Ames, B. N. Singlet oxygen DNA damage: Chromatograpic and mass spectrometric analysis of damage products. Methods Enzymol. 234:79-87; 1994.
184. Aruoma, O. I. Experimental tools in free radical biochemistry. In: Aruoma, O. I., ed. In: Free radicals in tropical diseases. London: Harwood Academic Publishers; 1993:233-267.
185. Palmer, R. M. J.; Ferrige, A. G.; Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526; 1987.
186. Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chandhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 84:9265-9269; 1987.
187. Butler, A. R.; Flitney, F. W.; Williams, D. L. H. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron nitrosyls in biology: A chemist's perspective. Trends Pharmacol. Sci. 16:18-22; 1995.
188. Hogg, N.; Kalyanaraman, B.; Joseph, J.; Struck, A.; Parthasarathy, S. Inhibition of low density lipoprotein oxidation by nitric oxide. FEBS Lett. 334:170-174; 1993.
189. Padmaja, S.; Huie, R. E. The reaction of nitric oxide with organic peroxyl radicals. Biochem. Biophys. Res. Commun. 195:539-544; 1993.
190. Sessa, W. C.; Pritchard, K.; Seyedi, N.; Wang, J.; Hintze, T. H. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ. Res. 74:349-353; 1994.
191. Weiss, S. J. Tissue destruction by neutrophils. N. Eng. J. Med. 320:365-376; 1989.
192. Kalyanaraman, B.; Sohnle, P. G. Generation of free radical intermediates from foreign compounds by neutrophil-derived oxidants. J. Clin. Invest. 75:1618-1622; 1985.
193. Travis, J.; Salvesen, G. S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52:655-709; 1983.
194. 1-antiproteinase by hypochlorous acid and by hydrogen peroxide. Biochem. J. 243:219-223; 1987.
195. Brooks, P. M.; Kean, W. F.; Buchanan, W. W. The clinical pharmacology of anti-inflammatory agents. London: Taylor & Francis; 1986.
196. Lewis, A. J.; Furst, D. E. Nonsteroidal anti-inflammatory drugs. Mechanism and clinical uses. 2nd ed. New York: Marcel Dekker Inc.; 1994.
197. Vane, J.; Botting, R. Inflammation and the mechanism of anti-inflammatory drugs. FASEB J. 1:89-96; 1987.
198. Belch, J. J. F. Eicosanoids and rheumatology, inflammatory and vascular aspects. Prostaglandins Leukot. Essent. Fatty Acids Rev. 36:219-234; 1989.
199. Sewell, K. L.; Trentham, D. E. Pathogenesis of rheumatoid arthritis. Lancet 341:283-290; 1993.
200. Brooks, P. M. Medical management of rheumatoid arthritis: Slow acting drugs. Rheumatol. Rev. 1:137-145; 1992.
201. Day, R. O.; Graham, G. G.; Williams, K. M. Pharmacokinetics of nonsteroidal antiinflammatory drugs. Bailliere's Clin. Rheumatol. 2:363-393; 1988.
202. Winyard, P. G.; Blake, D. R., eds. Immunopharmacology of inflammation. London: Academic Press; 1995.
203. McCord, J. M. Free radicals and inflammation. Protection of synovial fluid by superoxide dismutase. Science 185:529-531; 1974.
204. Halliwell, B.; Gutteridge, J. M. C.; Blake, D. Metal ions and oxygen radical reactions in human inflammatory joint disease. Philos. Trans. R. Soc. Lond. [Biol] 311:659-671; 1985.
205. Dowling, E. J.; Symons, A. M.; Parke, D. V. Free radical production at the site of an acute inflammatory reaction as measured by chemiluminescence. Agents Actions 19:203-207; 1986.
206. Weiss, S. J. Oxygen, ischemia and inflammation. Acta Physiol. Scand. 548(S):9-37; 1986.
207. Babior, B. M. Oxygen-dependent microbial killing by phagocytes. N. Engl. J. Med. 298:721-725; 1978.
208. Hurst, N. P.; French, J. K.; Bel, A. L.; Nuki, G.; O'Donnell, M.; Betts, W. H.; Cleland, L. G. Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation phospholipid methylation and arachidonic acid release by human blood monocytes. Biochem. Pharmacol. 35:3083-3089; 1986.
209. Muller-Peddinghaus, R.; Wurl, M. The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers. Biochem. Pharmacol. 36:1125-1132; 1987.
210. Oyanagui, Y. Inhibition of superoxide anion production in non-stimulated guinea pig peritoneal exudate cells by antiinflammatory drugs. Biochem. Pharmacol. 27:777-782; 1978.
211. Ahnfelt-Rønne, I.; Nielsen, O. H.; Christensen, A.; Langholz, E.; Binder, V.; Riis, P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98:1162-1169; 1990.
212. Biemond, P.; Swaak, A. J. G.; Eijk, H. G.; Koster, J. F. Superoxide dependent iron release from ferritin in inflammatory diseases. Free Radic. Biol. Med. 4:185-198; 1988.
213. Aruoma, O. I.; Halliwell, B. The iron binding and hydroxyl radical scavenging action of antiinflammatory drugs. Xenobiotica 18:459-470; 1988.
214. Biemond, P.; Swaak, A. J. G.; Penders, J. M. A.; Biendorff, C. M.; Koster, J. F. Superoxide production by polymorphonuclear leukocytes in rheumatoid arthritis and osteoarthritis: In vivo inhibition of the antirheumatic drug piroxicam due to interference with the activation of the NADPH oxidase. Anal. Rheum. Dis. 45:249-255; 1986.
215. Miller, K. O.; Hodd, P. L.; Willson, R. L. Antiinflammatory drugs: Protection of a bacterial virus as an in vitro biological measure of free radical activity. Chem. Biol. Interact. 47:293-305; 1983.
216. Tamai, H.; Kachur, J. F.; Grisham, M. B.; Gaginella, T. S. Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidant possible contribution to the mechanism of action in inflammatory bowel disease. Biochem. Pharmacol. 41:1001-1006; 1991.
217. Flohe, L. Superoxide dismutase for therapeutic use: Clinical experience, dead ends and hopes. Mol. Cell. Biochem. 84:123-131; 1988.
218. Greenwald, R. A. Oxygen radicals, inflamation and arthritis: Pathophysical considerations and implications for treatment. Semin. Arthritis Rheum. 20:219-240; 1991.
219. Halliwell, B. Free radicals and rheumatoid disease. In: Henderson, B.; Edwards, J. C. W.; Pettipher, E. R., eds. Mechanism and models in rheumatoid arthritiseds. London: Academic Press. 1995:301-316.
220. Travis, J.; Salvesen, G. S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52:655-709; 1984.
221. Pekoe, G.; van Dyke, K.; Mengoli, H.; Peden, D.; English, D. Comparison of the effects of antioxidant nonsteroidal antiinflammatory drugs against myeloperoxidase and hypochlorous acid luminol enhanced chemiluminescence. Agents Actions 12:232-238; 1982.
222. Wasil, M.; Halliwell, B.; Moorhouse, C. P.; Hutchison, D. C. S.; Baum, H. Biologically significant scavenging of the myeloperoxidase-derived oxidant hypochlorous acid by some antiinflammatory drugs. Biochem. Pharmacol. 36:3847-3850; 1987.
223. 1-antitrypsin in fresh samples of synovial fluid from patients with rheumatoid arthritis. Ann. Rheum. Dis. 50:915-916; 1991.
224. Aruoma, O. I.; Wasil, M.; Halliwell, B.; Hoey, B. M.; Butler, J. The scavenging of oxidants by sulphasalazine and its metabolites. Biochem. Pharmacol. 36:3739-3742; 1987.
225. Watkinson, G. Sulphasalazine: A review of 40 years experience. Drugs 32(Suppl. 1):1-11; 1986.
226. Goldman, P.; Peppercorn, M. A. Sulphasalazine. N. Engl. J. Med. 293:20-23; 1975.
227. McConkey, B. History of the development of sulphasalazine in rheumatology. Drugs 31(Suppl. 1):12-17; 1986.
228. Azadkhan, A. K.; Piris, J.; Truelove, S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892-895; 1977.
229. Sack, D. M.; Peppercorn, M. A. Drug therapy of inflammatory bowel disease. Pharmacotherapy 3:158-176; 1983.
230. 1-antiproteinase by sulphur-containing radicals derived from penicillamine. Biochem. Pharmacol. 38:4353-4357; 1989.
231. Weiss, J. Radiochemistry of aqueous solutions. Nature 153:748-750; 1944.
232. 1-antiproteinase by phenylbutazone in the presence of haem proteins: Protection by ascorbic acid. Biochem. Pharmacol. 44:981-984; 1992.
233. Grisham, M. B.; Ware, K.; Marshall, S.; Yamada, T.; Sandhu, I. S. Pro-oxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects. Digest. Dis. Sci. 37:1383-1389; 1992.
234. Aruoma, O. I.; Grootveld, M.; Halliwell, B. The role of iron in ascorbate-dependent deoxyribose degradation. Evidence consistent with a site-specific hydroxyl radical generation caused by iron ions bound to the deoxyribose molecule. J. Inorg. Biochem. 29:289-299; 1987.
235. Gutteridge, J. M. C. Ferrous-salt promoted damage to deoxyribose and benzoate. The increased effectiveness of hydroxyl-radical scavengers in the presence of EDTA. Biochem. J. 243:709-714; 1987.
236. Bury, A.; Underbill, A. E.; Kemp, D. R.; O'Shea, N. J.; Smith, J. P.; Gomm, P. S. Metal complexes of antiinflammatory drugs. Part IV. Tenoxicam complexes of manganese (II), iron (III), cobalt(II), nickel(II) and copper(II). Inorg. Chim. Acta 138:85-89; 1987.
237. Harrison, D. O.; Thomas, R.; Underbill, A. E.; Everall, F. A.; Gomm, P. S.; Low, G. D. Metal complexes of antiinflammatory drugs. Part II. Azopropazone complexes of iron(III), cobalt (II), nickel (II), copper (II) and zinc (II). J. Coord. Chem. 14:107-112; 1985.
238. Grootveld, M.; Razi, M. T.; Sadler, P. J. Progress in the characterization of gold drugs. Clin. Rheumatol. 3:5-15; 1984.
239. Harrison, D. O.; Thomas, R.; Underbill, A. E.; Fletcher, J. K.; Gomm, P. S.; Hallway, F. Metal complexes of antiinflammatory drugs. I. Complexes of iron(III), cobalt(II), nickel(II), copper(II), zinc(II) with 4-hydroxy-3(5-methyl-3-isoxazolo-carbamyl)-2-methyl-2H-1,2-benzothiazine-1,1- dioxideisoxicam). Polyhedron 4:681-685; 1985.
240. Brown, D. H.; Smith, W. E.; Teape, J. W.; Lewis, A. J. Antiinflammatory effects of some copper complexes. J. Med. Chem. 23:729-734; 1980.
241. Sorenson, J. R. J. Copper complexes as radiation recovery agents. Chem. Brain 25:169-172; 1989.
242. Aruoma, O. I.; Halliwell, B.; Gajewski, E.; Dizdaroglu, M. Copper-ion dependent damage to the bases in DNA in the presence of hydrogen peroxide. Biochem. J. 273:601-604; 1991.
243. Blake, D. R.; Winyard, P.; Lunec, J. Cerebral and ocular toxicity induced by desferrioxamine. Q. J. Med. 56:345-351; 1985.
244. Claxson, A.; Morris, C.; Blake, D. R.; Siren, M.; Halliwell, B.; Gustafsson, T.; Lofkvist, B. The antiinflammatory effects of D-myo-inositol-1.2.6-triphosphate (PP56) on animal models of inflammation. Agents Actions 29:68-70; 1990.
245. Schöneich, C.; Dillinger, V.; von Bruchhausen, F.; Asmus, K. D. Oxidation of polyunsaturated fatty acids and lipids through thiyl and sulfonyl radicals. Reaction kinetics, and influence of oxygen and structure of thiyl radicals. Arch. Biochem. Biophys. 292:456-467; 1992.
246. 2 system. Drug Metab. Dispos. 19:184-187; 1991.
247. Evans, P. J.; Akanmu, D.; Halliwell, B. Promotion of oxidative damage to arachidonic acid and 1-antiproteinase by antiinflammatory drugs in the presence of the haem proteins myoglobin and cytochrome c. Biochem. Pharmacol. 48:2173-2179; 1994.
248. Aruoma, O. I.; Smith, C.; Cecchini, R.; Evans, P. J.; Halliwell, B. Free radical scavenging and inhibition of lipid peroxidation by β-blockers and by agents that interfere with calcium metabolism - A physiolgically relevant process? Biochem. Pharmacol 42:735-743; 1991.
249. Croft, K. A.; Dimmitt, S. B.; Moulton, C.; Beilin, L. J. Low density lipoprotein composition and oxidizability in coronary disease: Apparent favourable effect of beta blockers. Atherosclerosis 97:123-130; 1992.
250. Feuerstein, G. Z.; Yue, T.-L.; Cheng, H.-Y.; Ruffolo, R. R., Jr. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: Potential relevance of antioxidant activity. J. Hypertens. 11(Suppl 4):S41-S48; 1993.
251. Goncalves, T.; Carvalho, A. P.; Oliveira, C. R. Antioxidant effect of calcium antagonists on microsomal membranes isolated from different brain areas. Eur. J. Pharmacol. 204:315-322; 1991.
252. Janero, D. R.; Burghard, B. Antiperoxidant effect of dihydropyridine calcium antagonists. Biochem. Pharmacol. 38:4344-4348; 1989.
253. 2-receptor antagonists are scavengers of oxygen radicals. Eur. J. Clin. Invest. 24:476-481; 1994.
254. Nosalova, V.; Petrikova, M.; Nosal, R. Lipid peroxidation in normal and ulcerated gastric mucosa of rats treated with pentacaine and cimetidine. Agents Actions 27:160-162; 1989.
255. Constantin, M.; Bromont, C.; Fickat, R.; Massingham, R. Studies on the activity of bepridil as a scavenger of free radicals. Biochem. Pharmacol. 40:1615-1622; 1990.
256. Mak, I. T.; Weglicki, W. B. Protection by β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ. Res. 63:262-266; 1988.
257. 2+ chelators prevent DNA damage and protect hepatoma 1C1C7 cells from quinone-induced cell killing. Free Radical Res. Commun. 8:347-354; 1990.
258. Weglicki, W. B.; Mak, I. T.; Simic, M. G. Mechanisms of cardiovascular drugs as antioxidants. J. Mol. Cell Cardiol. 22:1199-1208; 1990.
259. Cantoni, O.; Sestili, P.; Cattabeni, F.; Bellomo, G.; Pou, S.; Cohen, M.; Cerutti, P. Calcium chelator quin 2 prevents hydrogen-peroxide-induced DNA breakage and cytotoxicity. Eur. J. Biochem. 182:209-212; 1989.
260. Mak, I. T.; Arroyo, C. M.; Weglicki, W. B. Inhibition of sarcolemmal carbon-centred free radical formation by propranolol. Circ. Res. 65:1151-1156; 1989.
261. Janero, D. R.; Lopez, R.; Pittman, J.; Burghardt, B. Propranolol as xanthine oxidase inhibitor: Implications for antioxidant activity. Life Sci. 44:1579-1588; 1989.
262. Aruoma, O. I.; Akanmu, D.; Cecchini, R.; Halliwell, B. Evaluation of the ability of the angiotensin-converting-enzyme inhibitor captopril to scavenge reactive oxygen species. Chem. Biol. Interact. 77:303-314; 1991.
263. Rauwald, H. W.; Behn, O.; Odenthal, K. P. Screening of nine vasoactive medicinal plants for their possible calcium antagonistic activity. Strategy of selection and isolation for the active principles of Olea europaea and Peucedanum ostruthium. Phytother. Res. 8:135-140; 1994.
264. King, V. F.; Garcia, M. L.; Himmel, D.; Reuben, J. P.; Lam, Y. K. T.; Pan, J. X.; Han, G. Q.; Kaczorowski, G. J. Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. J. Biol. Chem. 263:2238-2244; 1988.
265. Lupo, E.; Locher, R.; Weisser, B.; Vetter, W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol. Biochem. Biophys. Res. Commun. 203:1803-1808; 1994.
266. Sugawara, H.; Tobise, K.; Onodera, S. Absence of antioxidant effects of nifedipine and diltiazem on myocardial membrane lipid peroxidation in contrast with those of nisoldipine and propranolol. Biochem. Pharmacol. 47:887-892; 1994.
267. Mišik, V.; Mak, T. I.; Stafford, R. E.; Weglicki, W. B. Reaction of captopril and epicaptopril with transition metal ions and hydroxyl radicals: An EPR spectroscopy study. Free Radic. Biol. Med. 15:611-619; 1993.
268. Mira, M. L.; Silva, M. M.; Queiroz, M. J.; Manse, C. F. Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radic. Res. Commun. 19:173-181; 1993.
269. Engineer, F.; Sridhar, R. Inhibition of rat heart and liver microsomal lipid peroxidation by nifedipine. Biochem. Pharmacol. 38:1279-1285; 1989.
270. Zimmermann, J. J.; Zuk, S. M.; Millard, J. R. In vitro modulation of human neutrophil superoxide anion generation by various calcium channel antagonists used in ischemia reperfusion resuscitation. Biochem. Pharmacol. 38:3601-3610; 1989.
271. Simpson, P. J.; Lucchesi, B. R. Free radicals and myocardial ischemia and reperfusion. J. Lab. Clin. Med. 110:13-30; 1987.
272. Bolli, R. Mechanism of myocardial "stunning." Circulation 82:723-738; 1990.
273. Swales, J. D. Pharmacological treatment of hypertension. Lancet 344:380-385; 1994.
274. De Ponti, F.; Giaroni, C; Cosentino, M.; Lecchini, S.; Frigo, G. Calcium-channel blockers and gastrointestinal motility: Basic and clinical aspects. Pharmacol. Ther. 60:121-148; 1993.
275. 2+ in toxic cell killing. Trends Pharmacol. Sci. 10:281-285; 1989.
276. Bast, A. Oxidative stress and calcium homeostasis. In: Halliwell, B.; Aruoma, O. I., eds. DNA and free radicals. London: Ellis Horwood; 1993:97-108.
277. Ojcius, D. M.; Zychlinsky, A.; Zheng, L. M.; Young, J. D.-E. Ionophore-induced apoptosis: Role of DNA fragmentation and calcium fluxes. Exp. Cell Res. 197:43-49; 1991.
278. Yue, T. L.; McKenna, P. J.; Lysko, P. G.; Ruffolo, R. R., Jr.; Feuerstein, G. Z. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 97:209-216; 1992.
279. Jackson, C. L.; Bush, R. C.; Bowyer, D. E. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 80:17-26; 1989.
280. Parthasarathy, S.; Steinberg, D.; Witztum, J. L. The role of oxidized low density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med. 43:219-225; 1992.
281. Fuster, V.; Badimon, L.; Badimon, J. J.; Chesebro, J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Eng. J. Med. 326:242-250; 1992.
282. Daugherty, A.; Roselaar, S. E. Lipoprotein oxidation as a mediator of atherogenesis: Insights from pharmacological studies. Cardiovasc. Res. 29:297-311; 1995.
283. Ross, R. The pathogenesis of atherosclerosis. An update. N. Engl. J. Med. 314:488-500; 1988.
284. Parthasarathy, S.; Young, S. G.; Witztum, J. L.; Pittman, R. C.; Steinborg, D. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77:641-644; 1986.
285. Masana, L.; Bargallo, M. T.; Plana, N.; Larille, A.; Casala, I.; Sola, R. Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. Am. J. Cardiol. 68:863-867; 1991.
286. Halliwell, B. Oxidation of low density lipoproteins: Questions of initiation, propagation and the effect of antioxidants. J. Clin. Nutr. Suppl. 61:6708-6778; 1995.
287. Fisher, M.; Levine, P. H.; Doyle, E. M.; Arpano, M. M.; Hoogasian, J. J. A 21 aminosteroid inhibits oxidation of human low density lipoprotein by human monocytes and copper. Atherosclerosis 90:197-202; 1991.
288. Bruagher, J. M.; Pregenzer, J. F.; Chase, R. L.; Duncan, L. A.; Jacobsen, E. J.; McCall, J. M. Novel 21-amino steroids as potent inhibitors of iron dependent lipid peroxidation. J. Biol. Chem. 262:10438-10440; 1987.
289. Kuzuya, M.; Kuzuya, F. Probucol as an antioxidant and antiatherogenic drug. Free Radic. Biol. Med. 14:67-77; 1993.
290. Dale, H. H.; Laidlow, P. P. The physiolgoical action of β-iminazolylethylamine. J. Physiol. (Lond.) 41:318-344; 1910.
291. 2-receptor antagonists. Eur. J. Clin. Invest. 25(Suppl. 1):47-56; 1995.
292. Endov, M.; Levi, R. Histamine in the heart. Eur. J. Clin. Invest. 25 (Suppl. 1):5-11; 1995.
293. Bristow, M. R.; Ginsburg, R.; Harrison, D. C. Histamine and the human heart: The other receptor system. Am. J. Cardiol. 49:249-251; 1982.
294. 2-receptors. Nature 236:385-390; 1972.
295. Levi, R.; Rubin, L. E.; Gross, S. S. Histamine in cardiovascular function and dysfunction: Recent developments. Handbook Exp. Pharmacol 97:347-383; 1991.
296. Langtry, H. D.; Grant, S. M.; Goa, K. L. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 38:551-590; 1989.
297. Salin, A. S. Oxygen-derived free radicals and the prevention of duodenal ulcer relapse: A new approach. Am. J. Med. Sci. 300:1-6; 1990.
298. 2-receptor antagonists. Effects on myeloperoxidase-catalyzed reactions and hydroxyl radical generation in a ferrous-hydrogen peroxide system. Biochem. Pharmacol. 45:2389-2397; 1993.
299. Ramos, C. L.; Pou, S.; Rosen, G. M. Effect of antiinflammatory drugs on myeloperoxidase-dependent hydroxyl radical generation by human neutrophils. Biochem. Pharmacol. 49:1079-1084; 1995.
300. Edwards, C. R. W.; Padfield, P. L. Angiotensin-converting enzyme inhibitors: Past, present and bright future. Lancet i:29-34; 1985.
301. Salvetti, A. Newer ACE inhibitors: A look at the future. Drugs 40:800-828; 1990.
302. Williams, G. H. Converting enzyme inhibitors in the treatment of hypertension. N. Eng. J. Med. 319:1517-1525; 1988.
303. Leonetti, G.; Cuspidi, C. Choosing the right ACE inhibitor. A guide to selection. Drugs 49:516-535; 1995.
304. Antonaccio, M. J.; Cushman, D. W. Drugs inhibiting the reninangiotensin system. Fed. Proc. 40:2275-2284; 1981.
305. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345:669-685; 1995.
306. Mak, I. T.; Freedman, A. M.; Dickens, B. F.; Weglicki, W. B. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol. 40:2169-2175; 1990.
307. McMurray, J.; Chopra, M. Influence of ACE inhibitors on free radicals and reperfusion injury, pharmacological curiosity or therapeutic hope? Br. J. Clin. Pharmacol. 31:373-379; 1991.
308. Bagachi, D.; Prasad, R.; Das, D. K. Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem. Res. Commun. 158:52-57; 1989.
309. Baggot, J. E.; Morgan, S. L.; Ha, T.; Vaughan, W. H.; Hine, R. J. Inhibition of folate-dependent enzyme by non steroidal antiinflammatory drugs. Biochem. J. 282:197-202; 1992.
310. Rowley, D. A.; Gutteridge, J. M. C.; Blake, D. R.; Farr, M.; Halliwell, B. Lipid peroxidation in rheumatoid arthritis: Thiobarbituric acid-reactive material and catalytic iron salts in synovial fluid from rheumatoid patients. Clin. Sci. 66:691-695; 1984.
311. Selley, M. L.; Bourne, D. J.; Bartlett, M. R.; Tymms, K. E.; Brook, A. S.; Duffield, A. M.; et al. Occurrence of (E) 4-hydroxy-2-nonenal in plasma and synovial fluid of patients with rheumatoid arthritis and osteorarthritis. Ann. Rheum. Dis. 51:481-484; 1992.
312. Situnayake, R. D.; Thurnham, D. I.; Kootathep, S.; Chirico, S.; Lunec, J.; Davis, M.; et al. Chain-breaking antioxidant status in rheumatoid arthritis. Clinical and laboratory correlates. Ann. Rheum. Dis. 50:81-86; 1991.
313. Washko, P.; Rotrosen, D.; Levine, M. Ascorbic acid transport and accumulation in human neutrophils. J. Biol. Chem. 264:18996-19002; 1989.
314. Humad, S.; Zarling, E.; Clapper, M.; Skosey, J. K. Breath pentane excretion as marker of disease activity in rheumatoid arthritis. Free Radic. Res. Commun. 5:101-106; 1988.
315. Lunec, J.; Blake, D. R.; McCleary, S. J.; Brailsford, S.; Bacon, P. A. Self-perpetuating mechanisms of immunoglobulin G aggregation in rheumatoid inflammation. J. Clin. Invest. 76:2084-2090; 1985.
316. Chapman, M. L.; Rubin, B. R.; Gracy, R. W. Increased carbonyl content of proteins in synovial fluid from patients with rheumatoid arthritis. J. Rheumatol. 16:15-18; 1989.
317. Lunec, J.; Herbert, K.; Blount, S.; Griffiths, H. R.; Emery, P. 8-Hydroxydeoxyguanosine: A marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett. 348:131-138; 1994.
318. Ts'o, P. O. P.; Caspary, W. J.; Lorentzen, R. J. The involvement of free radicals in chemical carcinogenesis. In: Pryor, W. A., ed. Free radicals in biology, vol. III. San Diego: Academic Press; 1977:251-303.
319. Ames, B. N.; Gold, L. S. Chemical carcinogenesis too many rodent carcinogens. Proc. Natl. Acad. Sci. 87:7772-7776; 1990.
320. Shaw, I. C.; Jones, H. B. Mechanisms of nongenotoxic carcinogenesis. Trends Pharmacol. Sci. 15:89-93; 1994.
321. McBrien, D. C. H.; Slater, T. F., eds. Free radicals, lipid peroxidation and cancer. New York: Academic Press; 1982.
322. Babbs, C. F. Free radicals and the etiology of colon cancer. Free Radic. Biol. Med. 8:191-200; 1990.
323. Cerutti, P. A. Oxy-radicals and cancer. Lancet 344:862-863; 1994.
324. Weitzman, S. A.; Gordon, L. I. Inflammation and cancer: Role of phagocyte-generated oxidants in carcinogenesis. Blood 76:655-663; 1990.
325. Guyton, K. Z.; Kenzler, T. W. Oxidative mechanisms in carcinogenesis. Br. Med. Bull. 49:523-544; 1993.
326. Mason, R. P.; Rao, D. N. R. Thiyl free radical metabolites of thiol drugs, glutathione and proteins. Methods Enzymol. 186:318-328; 1990.
327. Mottley, C.; Toy, K.; Mason, R. P. Oxidation of thiol drugs and biochemicals by the lactoperoxidase/hydrogen peroxide system. Mol. Pharmacol. 31:417-421; 1987.
328. Uetrecht, J. P. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 24:299-366; 1992.
329. Uetrecht, J. P. Mechanism of drug-induced lupus. Chem. Res. Toxicol. 1:133-143; 1988.
330. Aruoma, O. I.; Halliwell, B.; Gajewski, E.; Dizdaroglu, M. Damage to the bases in DNA induced by hydrogen peroxide and ferric ion chelates. J. Biol. Chem. 264:20509-20512; 1989.
331. Marnet, L. J.; Burcham, P. C. Endogenous DNA adduct: Potential and paradox. Chem. Res. Toxicol. 6:771-785; 1993.
332. Dianzani, M. U. Lipid peroxidation and cancer. Crit. Rev. Oncol. Hematol. 15:125-147; 1993.
333. Cheeseman, K. H. Lipid peroxidation and cancer. In: Halliwell, B.; Aruoma, O. I. DNA and free radicals. London: Ellis Horwood; 1993:109-144.
334. Dangel, R. Lipid peroxidation - A common pathogenetic mechanism. Exp. Toxicol. Pathol. 44:169-181; 1992.
335. Cerutti, P. Pro-oxidant states and tumour promotion. Science 227:375-381; 1985.
336. Morrero, R.; Marnett, L. J. The role of organic peroxyl radicals in carcinogenesis. In: Halliwell, B.; Aruoma, O. I., eds. DNA and free radicals. London: Ellis Horwood; 1993:144-162.
337. Marnett, L. J. Peroxyl free radicals: Potential mediators of tumour initiation and promotion. Carcinogenesis 8:1365-1373; 1987.
338. Carson, D. A.; Ribeiro, J. M. Apoptosis and disease. Lancet 341:1251-1254; 1993.
339. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 11:121-139; 1992.
340. Vermes, I.; Haanen, C. Apoptosis and programmed cell death in health and disease. Adv. Clin. Chem. 31:177-246; 1994.
341. Levine, A. J. Tumour suppressor genes. Sci. Am. Sci. Med. Jan/Feb:28-37; 1995.
342. Oliner, J. D. The role of p53 in cancer development. Sci. Am. Sci. Med. Sept/Oct:16-25; 1994.
343. Hockenbery, D. M.; Oltvai, Z. N.; Yin, X.-M.; Milliman, C. L.; Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251; 1993.
344. Steinman, H. M. The Bcl-2 oncoprotein functions as a pro-oxidant. J. Biol. Chem. 270:3487-3490; 1995.
345. Powis, G.; Prough, R. A. Metabolism and action of anticancer drugs. London: Taylor & Francis; 1987.
346. Tounekti, O.; Pron, G.; Belehradek, J.; Mir, L. M. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalised. Cancer Res. 53:5462-5469; 1993.
347. Sinha, B. K. Free radicals in anticancer drug pharmacology. Chem. Biol. Interact. 69:293-317; 1989.
348. Keizer, H. G.; Pinedo, H. M.; Schuurhuis, G. J.; Joenje, H. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther. 47:219-231; 1990.
349. Powis, G. Free radical formation by antitumour quinones. Free Radic. Biol. Med. 6:63-101; 1989.
350. Allen, A. The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol 19:529-542; 1992.
351. Jordan, V. C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 110:507-517; 1993.
352. Ward, H. W. C. Antioestrogenic therapy for breast cancer: A trial of tamoxifen at two dose levels. Br. Med. J. i:13-14; 1973.
353. Cole, M. P.; Jones, C. T. A.; Todd, I. D. H. A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br. J. Cancer 25:270-275; 1971.
354. Fisher, B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res. 52:2371-2382; 1992.
355. Coezy, E.; Borgano, J. L.; Ruchefort, M. Tamoxifen and metabolites in MCF-7 cells. Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42:317-323; 1982.
356. Jordan, V. G.; Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumour agents. Endocr. Rev. 11:578-610; 1990.
357. Reddel, R. R.; Murphy, L. C.; Hall, R. E.; Sutherland, R. L. Differential sensitivity of human breast cancer cells to the growth-inhibitory effects of tamoxifen. Cancer Res. 45:1525-1531; 1985.
358. Croxtall, J. D.; Emmar, C.; White, J. O.; Choudhary, Q.; Flower, R. J. Tamoxifen inhibits growth of estrogen receptor-negative A549 cells. Biochem. Pharmacol. 47:197-202; 1994.
359. Lim, J. S.; Frenkel, K.; Troll, W. Tamoxifen suppress tumour promoter-induced hydrogen peroxide formation by human neutrophils. Cancer Res. 52:4969-4972; 1992.
360. Wiseman, H.; Laughton, M. J.; Arnstein, H. R. V.; Cannon, M.; Halliwell, B. The antioxidant action of tamoxifen and its metabolites. Inhibition of lipid peroxidation. FEBS Lett. 263:192-194; 1990.
361. Van Leeuwen, F. E.; Benraadt, J.; Coebergh, J. W. W.; Kiemeney, L. A. L. M.; Gimbrére, C. H. F.; Otter, R.; Schonten, L. J.; Damhuis, R. A. M.; Bontenbal, M.; Diepenhorst, F. W.; van den Belt-Dusebout, A. W.; Tinteren, H. V. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452; 1994.
362. Mani, C.; Gelboin, H. V.; Park, S. S.; Pearce, R.; Parkinson, A.; Kupfer, D. Metabolism of the antimammary cancer antiestorgenic agent. I. Cytochrome P-450 catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21:645-656; 1993.
363. Ruenitz, P. C.; Bagley, J. R.; Paper, C. W. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab. Dispos. 12:478-483; 1984.
364. Fromson, J. M.; Pearson, S.; Bramah, S. The metabolism of tamoxifen. Xenobiotica 3:693-714; 1973.
365. Mani, C.; Hodgson, E.; Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monoxygenase-mediated N-oxidation. Drug Metab. Dispos. 21:657-661; 1993.
366. Estape, J.; Milla, A.; Agusti, A.; Lloret, J. S.; Palacin, A.; Soriano, E. VP.16-213 (V16) and cyclophosphamide in the treatment of primitive lung cancer in phase M1. Cancer 43:72-77; 1979.
367. Slevin, M. L. The clinical pharmacology of etoposide. Cancer 67:319-329; 1991.
368. Sinha, B. K.; Trush, M. A.; Kalyanaraman, B. Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation. Biochem. Pharmacol. 32:3495-3498; 1983.
369. Loike, J. D.; Horwitz, S. B. Effect of VP-16-213 on the intracellular degradation of DNA in HeLA cells. Biochemistry 15:5443-5448; 1976.
370. Sun, X.-M; Snowden, R. T.; Dinsdale, D.; Ormerod, M. G.; Cohen, G. M. Changes in nuclear chromatin precede internucleosomal DNA cleavage in the induction of apoptosis by etoposide. Biochem. Pharmacol. 47:187-195; 1994.
371. D'Arpa, P.; Liu, L. F. Topoisomerase-targeting antitumour drugs. Biochim. Biophys. Acta 989:163-177; 1989.
372. Osheroff, N. Biochemical basis for the interaction of type I and type II topoisomerases with DNA. Pharmacol. Ther. 41:223-241; 1989.
373. Shahzeidi, S.; Sarnsfrand, B.; Jeffery, P. K.; McAnulty, R. J.; Laurent, G. J. Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur. Respir. J. 4:845-852; 1991.
374. Moldeus, P.; Cotgreave, I. A.; Berggren, M. Lung protection by a thiol-containing antioxidant: N-acetyl cysteine. Respiration 50(Suppl. 1):31-42; 1986.
375. Cotgreave, I. A.; Sandy, M. S.; Berggren, M.; Moldeus, P. W.; Smith, M. T. N-Acetylcysteine and glutathine-dependent protective effect of PZ51 (Ebselen) against diquat-induced cytotoxicity in isolated hepatocytes. Biochem. Pharmacol. 36:2899-2904; 1987.
376. Aruoma, O. I.; Halliwell, B.; Hoey, B. M.; Butler, J. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide and hypochlorous acid. Free Radic. Biol. Med. 6:593-597; 1989.
377. Pani, A.; Marongiu, M. E.; La Colla, P. Modulatory effect of N-acetylcysteine on the HIV-1 multiplication in chronically and acutely infected cell line. Antiviral Res. 22:31-43; 1993.
378. Villa, P.; Ghezzi, P. Effect of N-acetylcysteine on sepsis in mice. Eur. J. Pharmacol. 292:341-344; 1995.
379. Miguel, J.; Ferrandiz, M. L.; De Juan, E.; Sevila, I.; Martinez, M. N-Acetylcysteine protects against age related decline of oxidative phosphorylation in liver mitochondria. Eur. J. Pharmacol. 292:333-335; 1995.
380. de Rojas-Walker, T.; Tamir, S.; Hong, J.; Wishnok, J. S.; Tannenbaum, S. R. Nitric oxide induces oxidative damage in addition to deamination in macrophage DNA. Chem. Res. Toxicol. 8:473-477; 1995.
381. 2-receptor antagonist with potent gastric mucosal protective properties. Br. J. Pharmacol. 115:57-66; 1995.
382. Singh, G.; Ramey, D. R.; Morfeld, D.; Fries, J. F. Comparative toxicity of nonsteroidal antiinflammatory agents. Pharmacol. Ther. 62:175-191; 1994.
383. 10, beta-carotene, canthaxanthin, and (+)-catechin against oxidative damage to rat blood and tissues in vivo. Free Radic. Biol. Med. 18:949-953; 1995.
384. McCord, J. M.; Fridovich, I. Superoxide dismutases: A history. In; Michelson, A. M.; McCord, J. M.; Fridovich, I., eds. Superoxide and superoxide dismutases. London: Academic Press; 1977:1-10.
385. McCord, J. M.; Fridovich, I. The reduction of cytochrome c by milk xanthine oxidase. J. Biol. Chem. 243:5753-5760; 1968.
386. Butler, J.; Land, E. J.; Swallow, A. J. Chemical mechanisms of the effects of high energy radiation on biological systems. Radiat. Phys. Chem. 24:273-283; 1984.
387. Fridovich, I.; Handler, P. Detection of free radicals generated during enzymic oxidations by the initiation of sulfite oxidation. J. Biol. Chem. 236:1836-1840; 1961.
388. Fridovich, I. Competitive inhibition by myoglobin of the reduction of cytochrome c by xanthine oxidase. J. Biol. Chem. 237:584-596; 1962.
389. Bannister, J. V.; Hill, H. A. O. Chemical and biochemical aspects of superoxide and superoxide dismutase. New York: Elsevier North Holland; 1980.
390. Bannister, W. H.; Bannister, J. V. Biological and clinical aspects of superoxide and superoxide dismutase. New York: Elsevier North Holland; 1980.
391. Oberley, L. W. Superoxide dismutase, vol. I-III. Boca Raton: CRC Press; 1982; 1985.
392. Deng, H.-X.; Hentati, A.; Tainer, J. A.; Igbal, Z.; Cayabyab, A.; Hung, W. Y.; Getzoff, E. D.; Hu, P.; Herzfeldt, B.; Roos, R. P.; Warner, C.; Deng, G.; Sariane, E.; Smyth, C.; Parge, H. E.; Ahmed, A.; Roses, A. D.; Hallewell, R. A.; Pericak-Vance, M. A.; Siddique, T. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 261:1047-1051; 1993.
393. Seddon, J. M.; Ajani, U. A.; Sperduto, R. D.; Hiller, R.; Blair, N.; Burton, T. C; Farber, M. D.; Gragoudas, E. S.; Haller, J.; Miller, D. T.; Yannuzzi, L. A.; Willett, W. Dietary carotenoids, vitamins A, C and E and adanced age related macular degeneration. JAMA 272:1413-1420; 1994.
394. Swallow, A. J. The radiation chemistry of ethanol and diphosphopyridine nucleotide and its bearing on dehydrogenase action. Biochem. J. 54:253-257; 1953.
395. Waters, W. A. A chemical interpretation of the mechanism of oxidation by dehydrogenase enzymes. Trans. Faraday Soc. 39:140-151; 1943.
396. Tappel, A. L.; Boyer, P. D.; Lundberg, W. O. The reaction mechanism of soybean lipoxidase. J. Biol. Chem. 199:267-271; 1952.
397. Muller, D. P. R. Vitamin E and neurological functions: Lessons from patients with abetalipoproteinaemia. Redox Rep. 1:239-245; 1995.
398. Yoshida, T.; Tanaka, M.; Sotomatsu, A.; Hirai, S. Activated microglia cause superoxide mediated release of iron from ferritin. Neurosci. Lett. 190:21-24; 1995.
399. Adams, J. D., Jr.; Odunze, I. N. Oxygen free radicals and Parkinson's disease. Free Radic. Biol. Med. 10:161-169; 1991.
400. Aruoma, O. I.; Halliwell, B. Superoxide-dependent and ascorbate-dependent formation of hydroxyl radicals from hydrogen peroxide in the presence of iron: Are lactoferrin and transferrin promoters of hydroxyl radical generation. Biochem. J. 241:273-278; 1987.
401. Halliwell, B.; Gutteridge, J. M. C. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol. 186:1-85; 1990.
402. Chevion, M.; Liang, Y.; Har-El, R.; Berenshtein, E.; Uretzky, G.; Kitrossky, N. Copper and iron are mobilised following myocardial ischemia: Possible productive criteria for tissue injury. Proc. Natl. Acad. Sci. 90:1102-1106; 1993.
403. Ramos, C. L.; Pou, S.; Britigan, B. E.; Cohen, M. S.; Rosen, G. M. Spin trapping evidence for myeloperoxidase-dependent hydroxyl radical formation by human neutrophils and monocytes. J. Biol. Chem. 267:8307-8312; 1992.
404. Brown, R. H. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice. Cell 80:687-692; 1995.
405. Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1609-1623; 1992.
406. Jenner, P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. 84(Suppl. 136):6-15; 1991.
407. Beard, J. L.; Cornor, J. R.; Jones, B. C. Iron in the brain. Nutr. Rev. 51:157-170; 1993.
408. Nalbandyan, R. M. Copper in brain. Neurochem. Res. 8:1211-1232; 1983.
409. Coyle, J. T.; Puttfarcken, P. Oxidative stress, glutamate and neurodegenerative disorders. Science 262:689-695; 1993.
410. Yoshikawa, T. Free radicals and their scavengers in Parkinson's disease. Eur. Neurol. 33(Suppl. 1):60-68; 1993.
411. Olanow, C. W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:439-444; 1993.
412. Gerlach, M.; Riederer, P.; Youdim, M. B. H. Neuroprotective therapeutic strategies, comparison of experimental and clinical results. Biochem. Pharmacol. 50:1-16; 1995.
413. Aruoma, O. I.; Bomford, A.; Polsen, R. J.; Halliwell, B. Non-transferrin bound iron in plasma from hemochromatosis patients: Effects of phlebotomy therapy. Blood 72:1416-1419; 1988.
414. Gutteridge, J. M. C.; Rowley, D. A.; Griffiths, E.; Halliwell, B. Low molecular weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin. Sci. 68:463-467; 1985.
415. von Sonntag, C. The chemical basis of radiation biology. London: Taylor & Francis; 1987.
416. Halpern, H. J.; Yu, C.; Barth, E.; Peric, M.; Rosen, G. M. In situ detection, by spin trapping of hydroxyl radical markers produced from ionizing radiation in the tumor of a living mouse. Proc. Natl. Acad. Sci. 92:796-800; 1995.
417. Fontham, E. T. H. Vitamin C, vitamin C-rich foods, and cancer: Epidemiologic studies. In: Frei, B., ed. Natural antioxidants in human health and disease. London: Academic Press; 1994:157-197.
418. Raynolds, J. E. F. Martindale: The extra pharmacopoeia. 29 ed. London: The Pharmaceutical Press; 1989.
419. Pettit, G. R.; Piersen, F. H.; Herald, C. L. Anticancer drugs from animals, plants and microorganisms. New York: John Wiley; 1994.
420. Speight, T. M., ed. Avery's drug treatment. Principles and practice of clinical pharmacology and therapeutics, 3rd ed. Auckland: ADIS Press; 1987.
421. Opie, L. H. Drugs for the heart, 3rd ed. Phaladelphia: W. B. Saunders; 1991.
422. Flohé, L. Glutathione peroxidase brought into focus. In: Pryor, W. A., ed. Free radicals in biology. New York: Academic Press; 1982:223-254.
423. van der Vliet, A.; Smith, D.; O'Neill, C. A.; Kaur, H.; Darley-Usmar, V.; Cross, C. E.; Halliwell, B. Interactions of peroxynitrite with human plasma and its constituents: Oxidative damage and antioxidant depletion. Biochem. J. 303:295-301; 1994.
424. Bomford, A. B.; Ward, R. J.; Crichton, R. R. Infuence of tropical diseases on iron metabolism. In: Aruoma, O. I., ed. Free radicals in tropical diseases. London: Harwood Academic Publishers; 1993:13-33.
425. Kirwan, J. R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N. Engl. J. Med. 333:142-146; 1995.
426. Tugwell, P.; Pincus, T.; Yocum, D.; Stein, M.; Gluck, O.; Kraag, G.; McKendry, R.; Tesser, J.; Baker, P.; Klells, G. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N. Engl. J. Med. 333:137-141; 1995.
427. Beckman, J. S.; Beckman, T. W.; Chen, J.; Marshall, P. A.; Freeman, B. A. Apparent hydroxyl radical production by peroxynitrite: Implication for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87:1620-1624; 1990.
428. Leurs, R.; Smit, M. J.; Timmerman, H. Molecular pharmacological aspects of histamine receptors. Pharmacol. Ther. 66:413-463; 1995.
429. Sagar, S. M.; Singh, G.; Hodsen, D. I.; Whitton, A. C. Nitric oxide and anticancer therapy. Cancer Treat Rev. 21:159-181; 1995.
430. Burkart, V.; Grob-Eick, A.; Bellman, K.; Radons, J.; Kolb, H. Suppression of nitric oxide toxicity in islet cells by α-tocopherol. FEBS Lett. 364:259-263; 1995.
431. Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012; 1993.
432. Lancaster, J., ed. The Biological Chemistry of Nitric Oxide. New York: Academic Press; 1995.
433. Stamler, J. S.; Singel, D. J.; Lescalzo, J. Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898-1902; 1992.
434. Culotta, E.; Koshland, D. E., Jr. NO news is good news. Science 258:1862-1865; 1992.
435. Freeman, B. Free radical chemistry of nitric oxide looking at the dark side. Chest 105:79S-84S; 1994.
436. Anggard, E. Nitric oxide:t Mediator, murderer and medicine. Lancet 343:1199-1206; 1994.
437. Rubbo, H.; Radi, R.; Trujillo, M.; Telleri, R.; Kalyanaraman, B.; Barnes, S.; Kirk, M.; Freeman, B. A. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. J. Biol. Chem. 269: 26066-26075; 1994.
438. White, C. R.; Brock, T. A.; Chang, L. Y.; Crapo, J.; Brisco, P.; Ku, D.; Bradley, W. A.; Gianturco, S. H.; Gore, J.; Freeman, B. A.; Tarpey, M. M. Superoxide and peroxynitrite in atherosclerosis. Proc. Natl. Acad. Sci. USA 91:1044-1048; 1994.
439. Tarpey, M. M.; Beckman, J. S.; Ischiropolous, H.; Gore, J. Z.; Brock, T. A. Peroxynitrite stimulates vascular smooth muscle cell cyclic GMP synthesis. FEBS Lett. 364:314-318; 1995.
440. Radi, R.; Beckman, J. S.; Bush, K. M.; Freeman, B. A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266:4244-4250; 1991.
441. Ischiropoulos, H.; Al-Mehdi, A. B. Peroxynitrite mediated oxidative protein modifications. FEBS Lett. 364:279-282; 1995.
442. Graham, A.; Hogg, N.; Kalyanaraman, B.; O'Leary, V.; Darley-Usmar, V.; Moncada, S. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 330: 181-185; 1993.
443. Vallance, P.; Patton, S.; Bhagar, K.; MacAllister, R.; Radomski, M.; Moncada, S.; Malinski, T. Direct measurement of nitric oxide in human beings. Lancet 346:153-155; 1995.
444. Archer, S. Measurement of nitric oxide in biological models. FASEB J. 7:349-360; 1993.
445. •) production in an activated macrophage culture with a radical scavenger, carboxy PTTO and Griess reagent. FEBS Lett. 368:425-428; 1995.
446. Salgo, M. G.; Stone, K.; Squadrito, G. L.; Battista, J. R.; Pryor, W. A. Peroxynitrite causes DNA nicks in plasmid pBR322. Biochem. Biophys. Res. Commun. 210:1026-1030; 1995.
447. Gaston, B.; Drazen, J. M.; Lescalzo, J.; Stamler, J. S. The biology of nitrogen oxide in the airways. Am. J. Respir. Crit. Care Med. 149:538-551; 1994.
448. Pryor, W. A.; Squadrito, G. L. The chemistry of peroxynitrite: A product from the reaction of nitric oxide with superoxide. Lung Cell. Mol. Physiol. 12:L699-L722; 1995.
449. Zhu, L.; Gunn, C.; Beckman, J. S. Bactericidal activity of peroxynitrite. Arch. Biochem. Biophys. 298:452-457; 1992.
450. Watts, B. P., Jr.; Barnard, M.; Turrens, J. F. Peroxynitrite-dependent chemiluminescence of amino acids, proteins and intact cells. Arch. Biochem. Biophys. 317:324-330; 1995.
451. Kalyanaraman, B.; Darley-Usmar, V.; Struck, A.; Hogg, N.; Parthasarathy, S. Role of apolipoprotein-derived radical and α-tocopheroxyl radical in peroxidase-dependent oxidation of low density lipoprotein. J. Lipid Res. 36:1037-1045; 1995.
452. Winterbourn, C. C. Factors that influence the deoxyribose exudation assay for Fenton reaction products. Free Radic. Biol. Med. 11:353-360; 1991.
453. Gutteridge, J. M. C.; Nagy, I.; Maidt, L.; Floyd, R. A. ADP-iron as a Fenton reactant: Radical reactions detected by spin trapping, hydrogen abstraction and aromatic hydroxylation. Arch. Biochem. Biophys. 277:422-428; 1990.
454. Parij, N.; Nagy, A. M.; Neve, J. Linear and non linear competition plots in the deoxyribose assay for determination of rate constants for reaction of nonsteroidal antiinflammatory drugs with hydroxyl radicals. Free Radic. Res. 23:571-579; 1995.
455. Aruoma, O. I.; Chaudhary, S. S.; Grootveld, M.; Halliwell, B. Binding of iron (II) ions to the pentose sugar 2-deoxyribose. J. Inorg. Biochem. 35:149-155; 1989.
456. Naock, H.; Kube Augustin, W. Relationship between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic. Res. 20:375-386; 1994.
457. Jeding, I.; Evans, P. J.; Akanmu, D.; Dexter, D.; Spencer, J. P. E.; Aruoma, O. I.; Jenner, P.; Halliwell, B. Characterization of the potential antioxidant and pro-xodiant actions of some neuroleptic drugs. Biochem. Pharmacol. 49:359-365; 1995.
458. Spencer, J. P. E.; Jenner, A.; Buttler, J.; Aruoma, O. I.; Dexter, D. T.; Jenner, P.; Halliwell, B. The pro-oxidant and antioxidant actions of L-DOPA and dopamine: Implications for Parkinson's disease. Free Radic. Res. 24:95-105; 1996.
459. Hu, M.-L.; Chen, Y. K.; Lin, Y.-F. The antioxidant and pro-oxidant activity of some B vitamins and vitamin-like compounds. Chem. Biol Interact. 97:63-73; 1995.
460. Frankel, E. N.; Huang, S. W.; Kanner, J.; German, J. B. Interfacial phenomena in the evaluation of antioxidants: Bulk oils vs. emulsions. J. Agric. Food Chem. 42:1054-1059; 1994.
461. Frankel, E. N. In search of better methods to evaluate natural antioxidants and oxidative stability in food lipids. Trends Food Sci. Technol. 4:220-225; 1993.
462. Pryor, W. A.; Strickland, T.; Church, D. F. Comparison of the efficiencies of several natural and synthetic antioxidants in aqueous sodium dodecyl sulfate micelle solutions. J. Am. Chem. Soc. 110:2224-2229; 1988.
463. Aruoma, O. I. Use of DNA damage as a measure of pro-oxidant actions of antioxidant food additives and nutrient components. In: Halliwell, B.; Aruoma, O. I., eds. DNA and free radicals. London: Ellis Horwood; 1993:315-327.
464. 2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ. Res. 77:335-341; 1995.
465. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368:225-229; 1995.
466. Miller, R. A.; Britigan, B. Protease-cleaved iron transferrin augments oxidant-mediated endothelial cell injury via hydroxy radical formation. J. Clin. Invest. 95:2491-2500; 1995.
467. Banni, S.; Day, B. W.; Evans, R. W.; Corongiu, F. P.; Lombardi, B. Detection of conjugated diene isomers of linoleic acid in liver lipids of rats fed a choline-devoid diet indicates that the diet does not cause lipoperoxidation. Nutr. Biochem. 6:281-289; 1995.
468. George, P. The chemical nature of the second hydrogen peroxide compound formed by cytochrome c peroxidase and horseradish peroxidase. Titration with reducing agents. Biochem. J. 54:267-276; 1953.
469. Hockenbery, D. M. bcl-2, a novel regulator of cell death. BioEssays 17:631-638; 1995.
470. Porter, N. A.; Caldwell, S. E.; Mills, K. A. Mechanism of free radical oxidation of unsaturated lipids. Lipids 30:277-290; 1995.
471. Gatti, R. M.; Augusto, O.; Kwee, J. K.; Giorgio, S. Leishmanicidal activity of peroxynitrite. Redox Rep. 1:261-265; 1995.
472. Armstrong, S. G.; Dean, R. T. A sensitive fluorometric assay for protein-bound DOPA and related products of radical-mediated protein oxidation. Redox Rep. 1:291-298; 1995.
473. Zhao, M. J.; Jung, L. Kinetics of the competitive degradation of deoxyribose and other molecules by hydroxyl radicals produced by the Fenton reaction in the presence of ascorbate. Free Radic. Res. 23:229-243; 1995.